Market Cap 5.37B
Revenue (ttm) 8.51B
Net Income (ttm) 565.70M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 6.51
Profit Margin 6.65%
Debt to Equity Ratio 1.27
Volume 689,300
Avg Vol 608,568
Day's Range N/A - N/A
Shares Out 687.56M
Stochastic %K 23%
Beta 0.67
Analysts Sell
Price Target $11.10

Company Profile

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testin...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 34 935 71 22 00
Fax: 34 938 00 80 00
Address:
Parque Empresarial Can Sant Joan, Avinguda de la Generalitat, 152-158 Sant Cugat del Valles, Barcelona, Spain
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 10 at 6:18 PM
$GRFS RSI: 20.69, MACD: -0.1908 Vol: 0.37, MA20: 9.06, MA50: 9.15 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
notreload_ai
notreload_ai Mar. 10 at 3:52 PM
Morgan Stanley downgraded $GRFS stock to Equal Weight with a lower €11 price target, citing slowdowns in key products like albumin in China and alpha-1. https://notreload.xyz/albumin-slowdown-in-china-forces-grifols-downgrade/
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 3 at 6:26 PM
$GRFS RSI: 37.14, MACD: -0.0701 Vol: 0.25, MA20: 9.27, MA50: 9.20 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 27 at 7:46 PM
$GRFS Current Stock Price: $8.97 Contracts to trade: $9.0 GRFS Mar 20 2026 Call Entry: $0.43 Exit: $0.73 ROI: 69% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Rickycello
Rickycello Feb. 25 at 12:17 PM
$GRFS bear: 6.3€ base: 15.19€ bull: 21.2€ Intrinsic value: 23.88€ Sell price target: 14.61€ (24% margin) Reward / risk: -0.88 Risk / reward: -1.13
0 · Reply
NorthStarStats
NorthStarStats Feb. 19 at 2:18 AM
For anyone following along, I developed a Python-based statistical scanner to identify stocks with near-term institutional accumulation and upward price momentum. The market perked up a bit, but still very dangerous for the momentum trader. Stock picks from the scanner: $GPN Score 98.00, $PLRX Score 98.00, $AWK Score 95.00, $APA Score 71.00, $GRFS Score 70.00
0 · Reply
WoodnighthawkFund
WoodnighthawkFund Feb. 18 at 4:19 PM
$GRFS Grifols operates plasma-derived therapies with global demand. Debt reduction and margin recovery are key catalysts. Pricing and regulatory factors affect outlook.
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 9 at 9:36 PM
$GRFS Share Price: $9.56 Contract Selected: Aug 21, 2026 $10 Calls Buy Zone: $0.04 – $0.05 Target Zone: $0.08 – $0.10 Potential Upside: 76% ROI Time to Expiration: 192 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
MeanReversionGroup
MeanReversionGroup Feb. 4 at 11:55 AM
$GRFS is a Spanish plasma-derived therapeutics company; it faces pricing pressure in Europe and needs to improve its plasma collection cost efficiency.
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 29 at 7:59 PM
$GRFS Share Price: $9.20 Contract Selected: Aug 21, 2026 $10 Calls Buy Zone: $0.38 – $0.47 Target Zone: $0.70 – $0.86 Potential Upside: 74% ROI Time to Expiration: 203 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Latest News on GRFS
Grifols: I'm Very Happy To Add In 2026

Wed, 11 Mar 2026 21:36:20 -0400 - 5 days ago

Grifols: I'm Very Happy To Add In 2026


Full Year 2025 Grifols SA Earnings Call Transcript

2026-02-26T23:48:34.000Z - 18 days ago

Full Year 2025 Grifols SA Earnings Call Transcript


Grifols, S.A. (GIKLY) Q4 2025 Earnings Call Transcript

Thu, 26 Feb 2026 17:27:54 -0500 - 18 days ago

Grifols, S.A. (GIKLY) Q4 2025 Earnings Call Transcript


Grifols (GRFS) Projects Strong Financial Performance by 2026

2026-02-26T17:26:12.000Z - 18 days ago

Grifols (GRFS) Projects Strong Financial Performance by 2026


Grifols doubles net profit in 2025, driven by revenues

Feb 26, 2026, 11:55 AM EST - 18 days ago

Grifols doubles net profit in 2025, driven by revenues

GRFS


White Falcon: Q4 2025 Portfolio Positions

Mon, 26 Jan 2026 21:15:00 -0500 - 7 weeks ago

White Falcon: Q4 2025 Portfolio Positions


Grifols: Positive/Neutral Scenario Posits An Upside

Mon, 08 Dec 2025 12:02:09 -0500 - 3 months ago

Grifols: Positive/Neutral Scenario Posits An Upside


Grifols, S.A. (GIKLY) Q3 2025 Earnings Call Transcript

Wed, 05 Nov 2025 16:11:15 -0500 - 4 months ago

Grifols, S.A. (GIKLY) Q3 2025 Earnings Call Transcript


Top Biotech Stocks Riding The Rally

Tue, 04 Nov 2025 15:15:35 -0500 - 4 months ago

Top Biotech Stocks Riding The Rally


4 Best Value And Growth Stocks (Yes, They Can Coexist)

Thu, 30 Oct 2025 08:00:00 -0400 - 4 months ago

4 Best Value And Growth Stocks (Yes, They Can Coexist)


My Top 5 Biotech Stocks Big Pharma Could Buy Next

Mon, 06 Oct 2025 13:29:00 -0400 - 5 months ago

My Top 5 Biotech Stocks Big Pharma Could Buy Next


Grifols: Significant Upside Likely Materializing

Thu, 02 Oct 2025 21:23:20 -0400 - 5 months ago

Grifols: Significant Upside Likely Materializing


Grifols: If This Works Out, It Has Massive Upside

Thu, 22 May 2025 12:09:37 -0400 - 10 months ago

Grifols: If This Works Out, It Has Massive Upside


Grifols, S.A. (GRFS) Q1 2025 Earnings Conference Call Transcript

Mon, 12 May 2025 16:51:03 -0400 - 11 months ago

Grifols, S.A. (GRFS) Q1 2025 Earnings Conference Call Transcript


Grifols: Looking At The Longer-Term 2025-2027 Upside After No Sale

Thu, 27 Feb 2025 12:58:12 -0500 - 1 year ago

Grifols: Looking At The Longer-Term 2025-2027 Upside After No Sale


Grifols' sales rise over 10% in 2024, above target

Feb 26, 2025, 12:18 PM EST - 1 year ago

Grifols' sales rise over 10% in 2024, above target

GRFS


Flat Footed Calls for Prompt Governance Overhaul at Grifols

Dec 10, 2024, 12:23 PM EST - 1 year ago

Flat Footed Calls for Prompt Governance Overhaul at Grifols

GRFS


Grifols: More Attractive Than In A Very Long Time

Fri, 29 Nov 2024 12:30:19 -0500 - 1 year ago

Grifols: More Attractive Than In A Very Long Time


Grifols: Here Is Why It's Still A 'Buy' Even If Price Goes Down

Thu, 03 Oct 2024 17:20:55 -0400 - 1 year ago

Grifols: Here Is Why It's Still A 'Buy' Even If Price Goes Down


OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 10 at 6:18 PM
$GRFS RSI: 20.69, MACD: -0.1908 Vol: 0.37, MA20: 9.06, MA50: 9.15 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
notreload_ai
notreload_ai Mar. 10 at 3:52 PM
Morgan Stanley downgraded $GRFS stock to Equal Weight with a lower €11 price target, citing slowdowns in key products like albumin in China and alpha-1. https://notreload.xyz/albumin-slowdown-in-china-forces-grifols-downgrade/
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 3 at 6:26 PM
$GRFS RSI: 37.14, MACD: -0.0701 Vol: 0.25, MA20: 9.27, MA50: 9.20 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 27 at 7:46 PM
$GRFS Current Stock Price: $8.97 Contracts to trade: $9.0 GRFS Mar 20 2026 Call Entry: $0.43 Exit: $0.73 ROI: 69% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Rickycello
Rickycello Feb. 25 at 12:17 PM
$GRFS bear: 6.3€ base: 15.19€ bull: 21.2€ Intrinsic value: 23.88€ Sell price target: 14.61€ (24% margin) Reward / risk: -0.88 Risk / reward: -1.13
0 · Reply
NorthStarStats
NorthStarStats Feb. 19 at 2:18 AM
For anyone following along, I developed a Python-based statistical scanner to identify stocks with near-term institutional accumulation and upward price momentum. The market perked up a bit, but still very dangerous for the momentum trader. Stock picks from the scanner: $GPN Score 98.00, $PLRX Score 98.00, $AWK Score 95.00, $APA Score 71.00, $GRFS Score 70.00
0 · Reply
WoodnighthawkFund
WoodnighthawkFund Feb. 18 at 4:19 PM
$GRFS Grifols operates plasma-derived therapies with global demand. Debt reduction and margin recovery are key catalysts. Pricing and regulatory factors affect outlook.
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 9 at 9:36 PM
$GRFS Share Price: $9.56 Contract Selected: Aug 21, 2026 $10 Calls Buy Zone: $0.04 – $0.05 Target Zone: $0.08 – $0.10 Potential Upside: 76% ROI Time to Expiration: 192 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
MeanReversionGroup
MeanReversionGroup Feb. 4 at 11:55 AM
$GRFS is a Spanish plasma-derived therapeutics company; it faces pricing pressure in Europe and needs to improve its plasma collection cost efficiency.
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 29 at 7:59 PM
$GRFS Share Price: $9.20 Contract Selected: Aug 21, 2026 $10 Calls Buy Zone: $0.38 – $0.47 Target Zone: $0.70 – $0.86 Potential Upside: 74% ROI Time to Expiration: 203 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 15 at 5:28 PM
$GRFS RSI: 52.13, MACD: 0.0563 Vol: 0.18, MA20: 9.16, MA50: 8.91 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 26 at 6:24 PM
$GRFS Current Stock Price: $9.02 Contracts to trade: $9.0 GRFS Jan 16 2026 Call Entry: $0.25 Exit: $0.49 ROI: 94% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
ResideRealm
ResideRealm Dec. 26 at 6:05 AM
$GRFS Credibility now depends on repeatable results instead of isolated wins. Cash generation will determine how self-sustaining growth becomes. Sustained momentum may broaden institutional interest. Execution precision is the primary catalyst from here.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 25 at 3:49 PM
$GRFS RSI: 55.83, MACD: 0.0457 Vol: 0.15, MA20: 8.93, MA50: 8.97 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
JarvisFlow
JarvisFlow Dec. 8 at 4:08 PM
JP Morgan has adjusted their stance on Grifols ( $GRFS ), setting the rating to Neutral with a target price of 10.3 → 10.
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 5 at 11:14 AM
$GRFS Current Stock Price: $8.89 Contracts to trade: $10 GRFS Dec 19 2025 Call Entry: $0.05 Exit: $0.08 ROI: 68% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
topstockalerts
topstockalerts Nov. 27 at 7:32 PM
Grifols has appointed board member Tomás Dagá as vice chairman of Grifols Egypt (GEPD), the joint venture with the Egyptian government to deploy the country’s first full plasma production system for Egypt, Africa, and the Middle East. The project, launched under a 2020 agreement, involves nearly €280 million in investment and aims to secure the national supply of plasma-derived medicines. Grifols currently operates 16 donation centers in Egypt, plans to open four more in 2026, and is establishing an analysis laboratory and a central plasma logistics center. The first phase of the plasma processing plant is set to start operations next year. The initiative has already created around 1,200 high-skilled direct jobs and over 14,000 indirect and induced positions. Dagá will oversee industrial and regulatory consolidation, strengthen relations with Egyptian authorities, and accelerate the full operational rollout of the project. $GRFS
0 · Reply
Love_To_Learn
Love_To_Learn Nov. 7 at 1:03 PM
$RCAT will use the CAT portion of your name for part of the name for project with DON n Puerto Rico isolating R for markets R CELLS $RCEL accessing $CERS $GRFS
1 · Reply
BillionerOfKing
BillionerOfKing Nov. 4 at 12:31 PM
$GRFS Current Stock Price: $9.43 Contracts to trade: $10 GRFS Nov 21 2025 Call Entry: $0.32 Exit: $0.40 ROI: 26% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
etrain2000
etrain2000 Nov. 3 at 1:45 AM
$GRFS Where is everyone hiding! Havent seen yall since earnings!
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 3 at 2:31 PM
$GRFS Brilliant piece that captures GRFS's situation perfectly. So if you want to update your understanding of GRFS or get to know GRFS better, this is essential reading. https://beyondspx.com/quote/GRFS/analysis/grifols-nasdaq-grfs-plasma-powerhouse-unleashes-growth-and-deleveraging-momentum
0 · Reply
topstockalerts
topstockalerts Sep. 26 at 5:04 PM
U.S. plans for new pharmaceutical tariffs are seen as negative due to uncertainty but could be an “opportunity” for Grifols, which is fully vertically integrated in the U.S. Banco Sabadell analysts noted the 100% tariff announcement on foreign branded or patented drugs unless companies establish U.S. manufacturing. While the news creates noise, details remain unclear, especially for firms already present in the U.S. Sanofi has announced $ 20B investment in the U.S. through 2030. Grifols is expected to face no negative impact, with ~70% of plasma collection and ~65% of production capacity in the U.S. Analysts see tariffs as a potential advantage for Grifols, the only fully vertically integrated hemoderivatives company in the country. Almirall’s impact would be minimal (~4.5% of sales in the U.S.), and Rovi is unlikely to be affected due to no direct distribution or branded products in the U.S. $GRFS $SNY $ALM $ROVI
0 · Reply